PharmaTher Holdings (NCC0) Stock Overview

A specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. More details

NCC0 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Earnings have declined by 7% per year over past 5 years

Makes less than USD$1m in revenue (CA$0)

Does not have a meaningful market cap (€3M)

Highly volatile share price over the past 3 months compared to the German market

+ 1 more risk

NCC0 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW446,008 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

446,008 investors already sharing narratives

View all narratives

PharmaTher Holdings Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for PharmaTher Holdings
Historical stock prices
Current Share Price	CA$0.021
52 Week High	CA$0.10
52 Week Low	CA$0.017
Beta	2.34
1 Month Change	-23.64%
3 Month Change	-22.22%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-61.47%

Recent updates

Shareholder Returns

	NCC0	DE Pharmaceuticals	DE Market
7D	0%	-2.1%	-2.3%
1Y	n/a	42.4%	4.8%

Return vs Industry: Insufficient data to determine how NCC0 performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how NCC0 performed against the German Market.

Price Volatility

Is NCC0's price volatile compared to industry and market?
NCC0 volatility
NCC0 Average Weekly Movement	77.6%
Pharmaceuticals Industry Average Movement	4.9%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.9%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: NCC0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: NCC0's weekly volatility has increased from 56% to 78% over the past year.

About the Company

Founded	Employees	CEO	Website
2019	n/a	Fabio Chianelli	www.pharmather.com

PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company’s product pipeline includes KETARX, a ketamine hydrochloride injection for the treatment of Parkinson’s disease, Amyotrophic Lateral Sclerosis, complex regional pain, and anesthesia, procedural sedation as well as depression, surgical and pain management. It develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX wearable pump for the maintenance of general anesthesia for diagnostic, surgical procedures and pain indications.

PharmaTher Holdings Ltd. Fundamentals Summary

How do PharmaTher Holdings's earnings and revenue compare to its market cap?
NCC0 fundamental statistics
Market cap	€2.83m
Earnings (TTM)	-€684.08k
Revenue (TTM)	n/a

0.0x

P/S Ratio

-4.1x

P/E Ratio

Is NCC0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NCC0 income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$1.10m
Earnings	-CA$1.10m

Last Reported Earnings

Feb 28, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-0.012
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did NCC0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/15 12:20
End of Day Share Price	2026/09/15 00:00
Earnings	2026/02/28
Annual Earnings	2025/05/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PharmaTher Holdings Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Patrick Trucchio	H.C. Wainwright & Co.

PharmaTher Holdings Ltd.DB:NCC0 Stock Report